US regulatory status: approved.
pharma · Thyroid eye disease · Thyroid Eye Disease · VRDN
Viridian Pharma
Viridian Pharma Ltd
Viridian Pharma drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
200 Market Street, ELMWOOD PARK, NJ 07407, US HQ
2017 Founded
2 Employees
Public company Type
VRDN · NYSE Ticker
Company details
- Status
- Public
- HQ
- 200 Market Street, ELMWOOD PARK, NJ 07407, US
- Founded
- 2017
- Employees
- 2
- Programs
- 13
- Drugs
- 11
- Patents
- 3
Viridian Pharma pipeline
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Viridian Pharma drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
caffeine citrate
Nervous system (N06)US regulatory status: approved. Molecular target: Adenosine receptor.
- Target
- Adenosine receptor
- Mechanism
- Adenosine receptor antagonist
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Viridian Pharma in public FDA and regional records.
-
Development asset linked to Viridian Pharma in public FDA and regional records.
-
Development asset linked to Viridian Pharma in public FDA and regional records.
-
Development asset linked to Viridian Pharma in public FDA and regional records. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to Viridian Pharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Neuronal acetylcholine receptor; alpha4/beta2.
- Target
- Neuronal acetylcholine receptor; alpha4/beta2
- Mechanism
- Neuronal acetylcholine receptor; alpha4/beta2 agonist
-
Development asset linked to Viridian Pharma in public FDA and regional records.
-
US regulatory status: approved.